4.8 Article

124I Radiolabeling of a AuIII-NHC Complex for In Vivo Biodistribution Studies

期刊

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 59, 期 39, 页码 17130-17136

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202008046

关键词

anticancer; metallodrugs; N-heterocyclic carbenes; positron emission tomography; radiochemistry

资金

  1. EU Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Actions [746976]
  2. Severo Ochoa Centres of Excellence Programme by the Spanish State Research Agency [CEX2018-000867-S]
  3. Spanish Ministry of Economy and Competitiveness [CTQ2017-87637-R]
  4. Beneficentia Stiftung
  5. University of Pisa [PRA_2017_25]
  6. Austrian Science Fund (FWF) [L212, L568]
  7. Spanish MultiMetDrugs network [RED2018-102471-T]
  8. Austrian Science Fund (FWF) [L568, L212] Funding Source: Austrian Science Fund (FWF)
  9. Marie Curie Actions (MSCA) [746976] Funding Source: Marie Curie Actions (MSCA)

向作者/读者索取更多资源

Au(III)complexes with N-heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au-III-NHC complexes by direct oxidation with radioactive [I-124]I(2)as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au-III-to-Au(I)reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au-III-NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据